S R BLOOM Introduction
Several stressful stimuli have been used to assess pituitary growth hormone and adrenocorticotrophic hormone reserves, of which insulin induced hypoglycaemia is the most widely used. Implicit in the induction of hypoglycaemia is the necessity for continuous and close medical supervision. Furthermore, this test very often causes unpleasant effects. The test is also reported to give variable growth hormone responses under similar conditions.'
Over the past two decades hypothalamic factors have been described which selectively stimulate specific cell types of the adenohypophysis. The isolation and characterisation of thyrotrophin releasing hormone2 and luteinising hormone releasing hormone3 led to extensive clinical use of these factors combined with insulin hypoglycaemia as a combined test of anterior pituitary function. 4 Two further hypothalamic peptides have now been characterised and synthesised: growth hormone releasing factor5 and corticotrophin releasing factor. 6 Growth hormone releasing factor selectively stimulates the release of growth hormone in man7 and has been used in clinical studies in adults89 and children.'0' Corticotrophin releasing factor is effective in rat pituitary in stimulating release of adrenocorticotrophic hormone both in vitro'2 and in vivo.'3 Corticotrophin releasing factor also releases adrenocorticotrophic hormone with consequent increases in plasma cortisol in man,' '6 though it is generally thought to be less effective than insulin hypoglycaemia. normal volunteers. In these also there was no significant difference in the hormonal response between the two tests.
Cortisol- Figure 1 shows the changes in plasma cortisol values after both combined pituitary function tests in all patients except the one with Cushing's syndrome. The single patient with a history of external irradiation to the pituitary gland showed a considerably greater peak concentration (833 nmol/l; 30 tg/100 ml) in the releasing factor test than in the insulin combined test (360 nmol/l; 13 sg/100 ml). For all subjects combined the mean basal concentration was 346 (SEM 32) nmol/l (12-5 (1) (2) [tg/100 ml) before the releasing factor test rising to a mean peak of 719 (40) nmol/l (26-0 (1-4) pg/100 ml) at 60 minutes, and 404 (33) nmol/l (14-6 (1) (2) [ig/100 ml) before the insulin combined test rising to 604 (58) nmol/l (21-9 (2-1) ig/100 ml) at 90 minutes (p<OOOl). The mean maximal increment from basal was thus greater with the releasing factor test (373 (19) 13-5 (0 7) Rg/I00 ml) than with the insulin combined test (200 (11) nmol/l; 7-2 (0-4) Rg/100 ml) (p<O-Ol). In the nine normal volunteers the mean cortisol increment from basal was 408 nmol/l (14-8 ig/100 ml; range 104-705 nmol/l (3-8-25-5 Rg/100 ml)) during the releasing factor test and 173 nmol/l (6-3 [g/100 ml; range 135-444 nmol/l (4-9-16-1 tg/100 ml)) after the insulin combined test (p<O-Ol) (table II) . Growth hormone-The growth hormone response to the two combined pituitary function tests in the patients was compared (fig 2) after excluding two patients with high circulating concentrations of growth hormone due to active acromegaly. Basal growth hormone concentrations were similar in the 
Discussion
The usefulness of a combined test to assess anterior pituitary reserve has been clearly shown,423 but those studies used insulin induced hypoglycaemia as the stimulus for the release of growth hormone and cortisol. Growth hormone releasing factor and corticotrophin releasing factor specifically stimulate growth hormone and cortisol release respectively,76 and in our study the four releasing factors given in combination with arginine vasopressin did not produce significantly different release of thyroid stimulating hormone, luteinising hormone, follicle stimulating hormone, and prolactin from that with the conventional combined test using insulin. In the case ofprolactin it might be expected that the stress of insulin induced hypoglycaemia in the classical test would cause a greater response than the releasing factor test, but we did not find this. Nevertheless, both the cortisol and growth hormone responses were found to be significantly greater in both the group of normal subjects and the total group studied with the releasing factor test. This increased response appeared to result from the inclusion of arginine vasopressin, without vasopressin cortisol and growth hormone responses were similar to those seen with the insulin combined test. Although arginine vasopressin is well known to stimulate secretion of adrenocorticotrophic hormone and hence cortisol, its synergistic effect with secretion of growth hormone releasing factor in man has not been reported. Arginine vasopressin alone had no effect on growth hormone secretion, and more studies (that is, in animals and isolated tissues) are needed to explore the precise relation in this apparently pronounced synergistic action.
The insulin combined test assesses hypothalamic-pituitary reserve, while the releasing factor test measures the readily releasable pool of anterior pituitary hormones. Thus in some cases of tumours in the pituitary area where stalk or hypothalamic damage has occurred it would be expected that results ofthe releasing factor test would differ from those of the insulin combined test. Other forms of hypothalamic insufficiency-for example, after cranial irradiation-would also be expected to show a different response, and the releasing factor test in these circumstances would not assess the need for hormone replacement therapy. The releasing factor test, however, is a valid clinical test of pituitary disease alone, and absence of response has the same implication in these cases as the results ofan insulin combined test. The releasing factor test appears to be particularly valuable in assessing the extent of damage to pituitary function after surgery for pituitary tumours and also the success of pituitary ablation used in the treatment of hormone dependent cancers. In practical terms it is often known that pituitary tumours or other pituitary diseases exist and what is needed is a test ofpituitary function as such; the releasing factor test is eminently applicable in this setting. The current cost of the basic peptide components of this test is £65 and, when manpower is considered, it may therefore be cheaper overall than the insulin combined test when this new combined releasing factor test becomes available commercially.
In most subjects the peak growth hormone and cortisol responses reportedly occur within 30-60 minutes with the combined releasing factors.'8 Our study confirms this and suggests that pituitary function may be evaluated with a 60 minute test rather than the 120 minutes required with the insulin combined test. The growth hormone response to growth hormone releasing factor has been reported to vary within the same subject79 and further study of individuals' variation in their response to the releasing factor test would be ofinterest.
Arginine vasopressin in the low dose used in this study has not been reported to have side effects,20 and we observed no reactions in the subjects studied. It is worth noting that thyrotrophin releasing hormone, used in both tests, has rarely been recorded as associated with pituitary apoplexy. 24 Two studies using multiple releasing hormones without argine vasopressin have been reported in normal subjects.'8"-Our study reports the combined use of the four releasing factors together with vasopressin as a powerful test of the readily releasable pool of pituitary hormones in both normal subjects and patients with pituitary disorders. The releasing factor test is quicker and more pleasant than the insulin combined test. It is more feasible for use on an office basis (for example, not risking unconsciousness and not needing a supervised meal as required after insulin induced hypoglycaemia) and may well prove to be generally safer, reducing the level of professional attention required. This test of pituitary function therefore appears to be a very useful addition to the insulin combined test, and indeed in some circumstances may replace it. Further work is required to establish the particular indications for its clinical use.
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